Highest-materiality recent filing
Codexis Q1 revenue doubles to $15.2M; net loss narrows to $8.7M from $20.7M
Revenue $15.2M (up from $7.5M YoY); product gross margin 71% vs 55%.
Director Dennis Wolf resigns from Codexis Board; Esther Martinborough re-elected in class rebalance
Dennis Wolf resigned from the Board and Audit/Compensation Committees effective April 8, 2026, with no disagreement with the Company.
Codexis Q4 revenue jumps 81% to $38.9M, net income of $9.6M; FY2025 revenue up 19%
Q4 2025 revenue of $38.9M (up 81% YoY); net income $9.6M vs net loss of $10.4M in Q4 2024.
Codexis appoints Alison Moore CEO, cuts 24% workforce, signs $37.8M Merck deal; Q3 net loss $19.6M
Alison Moore appointed President and CEO effective Nov 7, 2025; Stephen Dilly becomes Executive Chairman.
Codexis Q2 revenue $15.3M beats consensus; net loss narrows to $13.3M from $22.8M YoY
Revenue $15.3M, beating $14.1M analyst consensus; net loss $13.3M ($0.16/sh) vs $22.8M ($0.32/sh) YoY.
Codexis stockholders approve 8M share plan amendment, elect two directors
Stockholders approved amendment to 2019 Incentive Award Plan, adding 8,000,000 shares for issuance.
Codexis Q1 revenue drops to $7.5M from $17.1M; net loss widens to $20.7M
Revenue $7.5M vs $17.1M in Q1 2024; decline due to $6M one-time Roche license and large orders in prior year.
Codexis board member Byron Dorgan to retire at 2025 annual meeting, will consult for one year
Byron Dorgan, director since 2011 and former Chairman, will not stand for reelection at the 2025 Annual Meeting.
Codexis appoints Cynthia Collins to Board of Directors as Class II director
Appointed effective March 28, 2025 as Class II director; term expires at 2027 annual meeting.
Codexis FY2024 revenue $59.3M, net loss $65.3M; guides 2025 revenue $64M-$68M
FY2024 total revenue $59.3M (-4% YoY ex-PAXLOVID); net loss $65.3M ($0.89/share) vs $76.2M ($1.12) in FY2023.
Codexis appoints Christos Richards to Board of Directors
Appointment effective January 14, 2025 as Class II director with term until 2027 annual meeting.
Codexis appoints Raymond De Vré to Board; adopts amended bylaws
Raymond De Vré appointed as Class I director effective Nov 7, 2024; term expires at 2026 annual meeting.
Codexis Q3 product rev $11.2M, net loss narrows to $20.6M; cash $90.3M
Total revenues $12.8M vs $9.3M YoY; product rev $11.2M vs $5.4M; R&D rev $1.7M vs $3.9M.
Codexis CFO Sriram Ryali departs; enters separation agreement with 75% target bonus and consulting
CFO Sriram Ryali ceased service on Sep 30, 2024; separation agreement entered on Oct 16, 2024.
Codexis appoints Alison Moore as CTO and Georgia Erbez as CFO effective Sept 30, 2024
Alison Moore, formerly a Board member, becomes CTO; resigned from Board and committees.
Codexis Q2 revenues fall 62% YoY to $8.0M; net loss widens; reiterates FY2024 guidance
Q2 total revenue $8.0M vs $21.3M YoY; product rev $6.3M vs $11.0M; R&D rev $1.7M vs $10.3M.
Codexis stockholders elect directors, ratify auditor, approve say-on-pay
Elected Esther Martinborough (49.4M for, 549K withheld) and H. Stewart Parker (44.0M for, 5.97M withheld) as directors for three-year terms.
Successfully synthesized a full-length siRNA oligonucleotide using ECO Synthesis enzymatic platform, including a conjugation moiety.
Codexis Q1 revenue up 32%, net loss narrows to $11.5M; reiterates FY guidance
Total revenue $17.1M (+32% YoY); product revenue $9.6M (+14%); net loss $11.5M vs $22.6M loss in Q1 2023.
Codexis dismisses BDO as auditor, appoints KPMG effective Feb 29, 2024
Audit Committee dismissed BDO USA, P.C. as independent registered public accounting firm on February 29, 2024.
Q4 net loss $7.2M ($0.10/sh); FY2023 net loss $76.2M ($1.12/sh). Excl PAXLOVID & impairment, adj FY net loss $50.8M ($0.74/sh).
Codexis director Jennifer Aaker will not stand for reelection at 2024 annual meeting
Dr. Aaker notified the Board on February 13 of her decision not to stand for reelection.
Codexis secures up to $40M term loan from Innovatus; $30M funded
First tranche of $30M funded on Feb 13, 2024; second $10M tranche available on milestones.
Codexis amends bylaws to revise 'Acting in Concert' definition and add severability clause
Board approved amended bylaws effective Feb 8, 2024, modifying the definition of 'Acting in Concert'.
On April 4, 2025, Byron L. Dorgan provided notice to the board of directors (the “Board”) of Codexis, Inc. (the “Company”) of his intention to retire and not to stand for reelection to the Board at the expiration of his current term at the Company’s 2025 Annual Meeting of Stockholders (the “2025 Annual Meeting”).
On March 28, 2025, the Board of Directors (the “Board”) of Codexis, Inc. (the “Company”), upon the recommendation of the Board’s Nominating and Corporate Governance Committee, appointed Cynthia Collins as a member of the Board as a Class II director, effective immediately.
On January 14, 2025, the Board of Directors (the “Board”) of Codexis, Inc. (the “Company”), upon the recommendation of the Board’s Nominating and Corporate Governance Committee (the “Nominating and Corporate Governance Committee”), appointed Christos Richards as a member of the Board as a Class II director, effective immediately.
appointed Raymond De Vré as a member of the Board as a Class I director, effective immediately.
Sriram Ryali ceased to serve as the Company’s Chief Financial Officer and principal financial and accounting officer effective as of September 30, 2024.
In connection with her appointment as Chief Technical Officer, Dr. Moore resigned from the Board and its committees, effective as of September 30, 2024.
On September 30, 2024, the Board appointed Georgia Erbez as the Company’s Chief Financial Officer, replacing Sriram Ryali in such role, effective September 30, 2024.
On September 30, 2024, the Board appointed Georgia Erbez as the Company’s Chief Financial Officer, replacing Sriram Ryali in such role, effective September 30, 2024.
On September 30, 2024, the board of directors (the “Board”) of Codexis, Inc. (the “Company” or “Codexis”) appointed Alison Moore, Ph.D., a current member of the Board, to serve as the Company’s Chief Technical Officer.
On February 13, 2024, Jennifer Aaker, Ph.D. provided notice to the board of directors (the “Board”) of Codexis, Inc. (the “Company”) of her intention not to stand for reelection to the Board at the expiration of her current term at the Company’s 2024 Annual Meeting of Stockholders (the “2024 Annual Meeting”).
Max materiality 0.80 · Median 0.60 · Most common event earnings